 |
 |
|
The detailed
information for the 2005 HBS Healthcare Club Conference panel
moderators and participants is listed below.
| Biotech Panel: Participant |
 |
Faraz Ali
Director of Marketing
Genzyme |
Faraz earned a degree
in Electrical Engineering (Biomedical concentration) from
Stanford University. After graduating, he participated in
the Edison Engineering Program at General Electric (GE)
Medical Systems, an entry level training program. This led
to a position in GE Corporate where he worked on
high-profile projects at several major GE and GE Capital
businesses. He graduated from HBS in 2001 with distinction
where he did a field study co-sponsored by HBS, KSG, and HMS
to work with the government of Malawi on their national AIDS
response plan.
He joined Genzyme in 2001 through their
Management Development Program. He has been involved in the
launch of two products for "orphan diseases", including
Fabrazyme for Fabry disease and Aldurazyme for
Mucopolysaccharidosis I (MPS I) disease. His current role is
Global Director for the MPS I/Aldurazyme program, with is
part of a joint venture with BioMarin Pharmaceuticals. In
this capacity he influences the overall strategic direction
of the program.
He is interested in new technologies,
biologics and devices, and business models that have the
potential to radically change the health care industry while
improving and extending life globally. He continues to take
evening classes through Harvard Extension School in topics
such as Oncology, Immunology, Pathophysiology, Molecular
Biology and Genetics, and Epidemiology.
|
| VC/Startups Panel: Participant |
 |
Peter Barrett, Ph.D.
Senior Partner
Atlas Ventures |
Peter Barrett is a
Senior Partner in the life sciences sector and joined Atlas
Venture in 2002. Previously, he was a co-founder, Executive
Vice President and Chief Business Officer of Celera
Genomics. Within two years of the founding of the company
(1998), Celera announced the first successful sequencing of
the human genome. Peter helped launch Celera as a publicly
traded entity in 1999, and it became a leading force within
the biotechnology industry with annual revenues of over $100
million. Peter led Celera¡¯s expansion into drug discovery
and development, forging strategic alliances with technology
companies and leading the acquisition of Axys
Pharmaceuticals.
Prior to Celera, Peter held senior management positions at
The Perkin-Elmer Corporation, most recently serving as Vice
President, Corporate Planning and Business Development.
During his tenure, he expanded the life science business
units through a series of licensing agreements, partnerships
and acquisitions including: Applied Biosystems, Tropix,
Molecular Informatics, PerSeptive Biosystems, and Genscope.
Also during this time, Peter co-founded Celera Genomics with
Dr. J. Craig Venter and the Applera Corporation management
team. Additional managerial roles included Executive Vice
President of the Applied Biosystems Division of
Perkin-Elmer.
Peter's past board appointments include: Chairman of the
Board of the Analytical and Life Science System Association,
HuBit Genomix, Genecore, Roche Strategic Alliance, and Sciex
Joint Venture. He continues to sit on the Board of Atlas
Venture investment Alnylam (NASDAQ: ALNY) and is Chairman of
Momenta Pharmaceuticals (NASDAQ: MNTA), both held IPOs in
2004. He currently sits on the Advisory Council of the
Barnett Institute of Chemical and Biological Analysis at
Northeastern University and is a member of the Partners
Healthcare Research Accelerator Program.
Peter received his Bachelor of Science in Chemistry from
Lowell Technological Institute (now known as the University
of Massachusetts, Lowell) and his Ph.D. in Analytical
Chemistry from Northeastern University. He also completed
Harvard Business School¡¯s Management Development Program.
|
| Biotech Panel: Participant |
 |
Dr. Paul Beresford
VP of New Technologies and Personalized Medicine
Ventana Medical Systems, Inc. |
Dr. Paul Beresford is
Vice President of New Technologies and Personalized Medicine
at Ventana Medical Systems, Inc. Ventana is the world¡¯s
leading supplier of automated diagnostic systems to the
anatomical pathology market. Their instrument and reagent
systems are used in clinical histology, cytology, and drug
discovery laboratories around the globe. Paul¡¯s group works
with oncology-focused pharmaceutical and biotechnology
companies identifying and commercializing companion
diagnostic products using Ventana¡¯s biomarker platform. He
received a Ph.D. in Immunology from the Sackler School of
Graduate Biomedical Sciences at Tufts University School of
Medicine, where he studied with Dr. Judy Lieberman. Before
joining Ventana, Paul was an Instructor and Junior
Investigator at the Center for Blood Research at Harvard
Medical School where his research focused on the elucidation
of a novel caspase-independent cell death pathway initiated
by the Cytotoxic T cell protease, Granzyme A.
|
| Payor/Provider Panel: Moderator |
 |
Ernst R. Berndt
Louis B. Seley Professor of Applied Economics
MIT Sloan School of Management |
The sources of
productivity growth and how productivity is measured are
topics that interest Professor Berndt. Professor Berndt has
implemented methods for adjusting prices for changes in
quality in the pharmaceutical, health care, personal
computer hardware, and prepackaged software industries. He
is an expert on the changing dynamics of the healthcare
industry, and has examined how innovations have affected the
costs of treating selected diseases over time. In other
recent research, Professor Berndt has assessed how illness
and its treatment affects individuals' ability to function
at work, and the impact of direct-to-consumer marketing of
prescription pharmaceuticals on drug utilization.
|
| Medical Devices Panel: Participant |
 |
Dr. Nissim Darvish
Partner
Pitango Venture Capital |
Dr. Nissim Darvish
joined Pitango in 2002.
Prior to that, Dr. Darvish was among the founders of Impulse
Dynamics, a highly successful developer of cardiovascular
implantable devices, and served as its CEO and President.
Earlier in his career, Dr. Darvish was a research fellow at
the US National Institute of Health in the fields of
neurobiology and electrophysiology. He has held numerous
academic and research appointments and has an extensive list
of awards, prizes, publications and published patents in his
field.
Dr. Darvish holds an M.D. (cum laude) and D.Sc. in Medical
Sciences from the Technion - Israel Institute of Technology.
He currently serves on the Board of Directors of QuantomiX,
SuperDimension, Vascular Biogenics, Atria, Inotek, dbMotion
and TopSpin.
Beside his venture activity, Dr. Darvish is an active
entrepreneur and has established several medical companies.
|
| VC/Startup Panel: Participant |
 |
Errol B. De Souza, Ph.D.
President & CEO
Archemix |
Dr. De Souza is
President, CEO and Director of Archemix Corporation, a
company focusing on the development of therapeutic aptamers.
Dr. De Souza has held various academic and industrial
positions including Chief of the Laboratory for Neurobiology
at the National Institute on Drug Abuse (1985-1990),
Director of CNS Research at the Du Pont Merck Pharmaceutical
Company (1990 ¨C 1992), Founder, Director and Executive Vice
President of R&D, Neurocrine Biosciences, Inc. (1992-1998),
Senior Vice President and Site Head of US Drug Innovation &
Approval (R&D) for Aventis Pharmaceuticals (1998-2002), and
President, CEO and Director of Synaptic Pharmaceuticals
(2002 ¨C 2003). He has edited 5 books and is an author of
approximately 270 original articles, chapters or reviews. He
has received numerous national and internationals awards and
has served on several Editorial Boards and National
Institutes of Health Committees as well as Board of
Directors of several companies. He received his B.A. (1976)
and Ph.D. (1981) from the University of Toronto, and
completed a postdoctoral fellowship in Neuroscience at The
Johns Hopkins University School of Medicine, Baltimore
(1983-1984).
|
| Payor/Provider Panel: Participant |
 |
Dr. Stephen Deutsch
Executive Vice President and Chief Medical Officer
Touchstone Health |
Dr. Stephen Deutsch
currently serves as Executive Vice President and Chief
Medical Officer of Touchstone Health (www.touchstone-health.com),
a Medicare-focused managed care organization. Prior to
joining Touchstone Health, he served as Senior Vice
President and National Medical Director of CareAdvantage, a
healthcare services consulting and resource company that
provides services designed to increase the efficiency,
quality, and cost effectiveness of healthcare services. Dr.
Deutsch was the Founder and President of Occupational Health
and Rehabilitation. He practiced as a Board Certified
Orthopedic Surgeon for 19 years after completing his
residency at Harvard University. In addition, Dr. Deutsch
served for two years in the USAF. Dr. Deutsch is widely
published and is a Clinical Associate Professor at Brown
University Medical School.
|
| Big Pharma Panel: Participant |
 |
Jeffrey Elton
Senior Vice President of Strategy and Global Chief Operating Officer
Novartis Institutes for BioMedical Research
(NIBR) |
In his role as Senior
Vice President of Strategy, Jeff leads the development of
strategies fulfilling NIBR's mission of discovering and
developing drugs where there is high unmet medical need,
integrating functions, and enhancing partnerships within
NIBR and across Novartis. He ensures that NIBR operations
fully support drug discovery mission and goals, and work
coherently with key external alliances. Jeff is also
responsible for forming and maintaining major academic
collaborations. In his role as COO, Jeff oversees Global
Research Operations, Finance, Human Resources, Research
Information Technology, Legal and Communications.
Prior to joining NIBR, Jeff had 15 years of experience as a
consultant to the pharmaceutical industry, most recently as
a partner in McKinsey & Company¡¯s Boston Office for
four-and-a-half years, where he co-led that firm¡¯s global
R&D Operations and Intellectual Property Strategy &
Management practices in the pharmaceutical and biotechnology
industries. He has been active in serving leading academic
medical centers and biotech firms in their research
strategies for more than a decade. Over the past three years
at McKinsey Jeff has led several NIBR and Novartis Pharma
projects.
Jeff holds a Ph.D. in Business Economics and marketing and a
M.B.A. in Finance and Statistics from the University of
Chicago Graduate School of Business.
|
| VC/Startups Panel: Participant |
 |
Cedric Francois, M.D., Ph.D.
Co-Founder, CEO and President
Potentia Pharmaceuticals, Inc. |
Cedric Francois
received his MD from the University of Leuven in Belgium,
after which he entered a residency in plastic pediatric
surgery. He became interested in hand transplantation and
moved to Louisville, KY to work with the team that performed
the first successful hand transplantation. During that
period he obtained his PhD in Physiology and took over the
helm of Potentia Pharmaceuticals, the startup that won the
HBS business plan competition in 2001. He restructured the
company, moved it from Cambridge to Louisville, KY and
converted it from a nanotechnology platform into a drug
discovery company. Potentia currently has two drug
candidates for dry macular degeneration in the pre-IND stage
and seeks to initiate clinical trials with one or more of
the candidates next year. Dr. Francois is an author on 16
peer-reviewed publications and is the inventor on numerous
patent applications.
|
| VC/Startup Panel: Participant |
 |
Ansbert K. Gadicke, M.D.
Founder & General Partner
MPM Capital |
Dr. Ansbert Gadicke is the Founder and a General Partner of the MPM Group. He led MPM's effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. He subsequently held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT, Harvard University and the German Cancer Research Center. He has published in leading scientific publications including Nature and Cell. Dr. Gadicke is a Director of Arriva, Cerimon Pharmaceuticals, Elixir, Omrix Biopharmaceuticals, Nuvios, Pharmasset, PharmAthene, and Xanodyne. He previously served as a Director of BioMarin (NASDAQ:BMRN), Coelacanth, Idenix Pharmaceuticals (NASDAQ:IDIX), Kourion, MediGene (Frankfurt:MDG), Viacell (NASDAQ:VIAC) and Transform. He is a member of Advisory Councils for Harvard Medical School and the Whitehead Institute at MIT. He serves as the Co-Chairman of the Alumni Association of the Whitehead Institute and serves on the Board of the National Venture Capital Association (NVCA).
|
| Payor/Provider Panel: Participant |
|
¡¡ |
Howard L. Golub M.D., Ph.D.
President
CareStat Inc. |
Dr. Golub received
his PhD in biomedical engineering from Massachusetts
Institute of Technology and his medical degree from Harvard
Medical School. He has an appointment at Boston University
School of Public Health in epidemiology and biostatistics.
He has served as a founder and CEO of several companies
devoted to the development of various diagnostic medical
devices and tests, specialized computer software and the
provision of management services to a fully-integrated
physician network.
|
| Affiliated Service Providers
Panel: Participant |
 |
Kevin Gorman
Managing Partner
Putnam Associates |
Kevin is the Managing
Partner and Founder of Putnam Associates. Prior to
establishing Putnam in 1988, Kevin worked for a consulting
firm ultimately acquired by The Bossard Group, working on
projects throughout Europe while based in London and
Stockholm. He was also with Corporate Decisions, Inc. (CDI),
a Bain & Company spin-off. Before entering consulting, Kevin
was a member of the White House staff under President Carter
and served as the Assistant to the Undersecretary of Energy.
Kevin received his BA from Boston College and his MBA from
the Harvard Business School. He is a frequent speaker on
issues of competitive strategy in pharmaceuticals both
domestically and internationally.
|
| Biotech Panel: Participant |
 |
Adrian H. B. Gottschalk
Associate Director of Corporate Strategy
Biogen Idec |
Adrian H. B.
Gottschalk is a graduate of the Sloan School of Management
at MIT and the joint Harvard Medical School / MIT Biomedical
Enterprise Program where he received his M.B.A. and S.M.
degrees respectively. Adrian's thesis focused on evaluating
the cost/benefits of PDUFA and improving the efficiency of
the later stages of the drug development process. Prior to
attending MIT, Mr. Gottschalk was a consultant for
PricewaterhouseCoopers in Dallas, TX.
Adrian currently works for Biogen Idec as an Associate
Director in the Oncology Strategic Business Unit in San
Diego. In his current role, Adrian is responsible for a
variety of activities around Biogen Idec¡¯s B-Cell portfolio.
Prior to joining the oncology group, Adrian worked in the
Corporate Strategy group in Cambridge. His work experience
during graduate school included a three-month internship in
the business planning and group at Biogen (now Biogen Idec),
where he focused on the launch of Amevive, a biologic
indicated for the treatment of psoriasis. He also was an
independent consultant to the business development group at
Allergan Pharmaceuticals.
|
| Payor/Provider Panel: Participant |
|
¡¡ |
Robert B. Harrington
Cofounder
Cambridge Management Group, Inc. |
Robert B. Harrington,
a co-founder of Cambridge Management Group, Inc., has a
particular strength in engaging physicians to be accountable
to each other and their health care community. He has had a
prominent role in most CMG projects, including those
involving clinical priority setting, physician-institution
relationships, strategic planning, and group
practice/physician organization development. He has been a
featured speaker at VHA, the Health Care Roundtable, Kennedy
School, and the Cerner Annual Conference. Before founding
CMG, Mr. Harrington was a director of APM, Inc., a national
health care management consulting firm, a co-founder and
Executive Vice President of Care One Group, Inc., developer
and manager of primary care medical offices in the Boston
area, and an administrator at St. Luke's-Roosevelt Hospital
Center in New York City. He is a graduate of Dartmouth
College and the Harvard Business School.
|
| VC/Startups Panel: Moderator |
 |
Robert F. Higgins
Managing General Partner
Highland Capital |
Bob has more than twenty years of experience in venture capital and has served as a director of many public and private companies. He is a former director of the National Venture Capital Association and President of the New England Venture Capital Association. Bob has been an investor in many successful healthcare services, medical technology and information technology companies. Some of the services companies he has backed are Community Health Systems (NYSE: CYH), Mariner Health Group (IPO/acquired), New England Critical Care (IPO/acquired), Renal Treatment Centers (IPO/acquired) and U.S. Labs. Bob's medical technology investments include AVEO Pharmaceuticals, Conor Medsystems (Nasdaq: CONR), Helicos BioSciences, Mitotix (Neuer Market: GPC Biotech AG), Origin Medsystems (acquired), PerSeptive Biosystems (IPO/acquired), Pervasis Therapeutics and PRAECIS PHARMACEUTICALS (Nasdaq: PRCS). In addition, Bob has also served on the boards of SmartBargains, Staples.com and WordWave.
Before co-founding Highland, Bob was a general partner at a Boston-based venture capital partnership. Immediately prior to entering venture capital, he spent four years as the Executive Director of the John A. Hartford Foundation. He also was the Chief Executive of the Clark Foundation and the Burden Foundation. Bob is a former Assistant to the U.S. Secretary of Commerce and an Assistant to the head of the international division of the U.S. Treasury.
Bob has served as Chairman of the Finance Committee of the Beth Israel Deaconess Medical Center. Currently, he is a member of the Advisory Board of the Department of Health Care Policy at Harvard Medical School and the Advisory Board of the Harvard - MIT Division of Health Sciences & Technology. Also, Bob is a faculty member at the Harvard Business School where he teaches courses in entrepreneurial management. He received his A.B. in History from Harvard College and his M.B.A. from Harvard Business School.
|
| Big Pharma Panel: Participant |
 |
Richard L. Hoddeson
Vice President of Finance
Pfizer, Inc. |
Rick is Vice
President, Operations Planning & Analysis in the Corporate
Finance Division of Pfizer Inc. His responsibilities include
establishing and coordinating the Company¡¯s planning and
budgeting processes, preparing financial forecasts, and
overseeing various facets of management reporting. He also
has financial responsibility for various Corporate support
functions including Information Technology and Human
Resources. Rick is a member of the Pfizer¡¯s Finance
Management Committee¡ªthe senior level decision-making body
for various financial matters. Rick has been with Pfizer for
twenty-one years serving in a host of financial positions in
the U.S. Pharmaceutical Division and at the Corporate level.
Rick has a BA in Economics from the University of
Pennsylvania and an MBA in Finance from the Wharton School.
|
| Medical Devices Panel: Participant |
 |
Clifford Holmes, Ph.D.
Vice President of Discovery and Scientific Support
Baxter |
As native of
Liverpool, England, Cliff Holmes graduated from the
University of Manchester in 1978 with a Ph.D. in
Pharmaceutical Microbiology, and completed a post-doctorial
research fellowship in 1980 at Harvard Medical School and
the Peter Bent Brigham Hospital, in Boston, Massachusetts.
He has worked for Baxter Healthcare for over 24 years in
both Europe and the US, and is currently Vice President of
Discovery and Scientific support for the Renal Division of
Baxter located in Illinois, U.S.A.
Cliff¡¯s research interests include infection control in the
dialysis setting, peritoneal access technologies, host
defense mechanisms in peritoneal dialysis patients,
bio-compatibility of hemodialysis and peritoneal dialysis
therapies, tissue engineering and stem cell approaches for
renal replacement therapies.
|
| Affiliated Service Providers Panel: Participant |
 |
Mason (Skip) Irving, III
Managing Director
Health Advances, LLC |
Prior to joining
Health Advances seven years ago, as Vice President for
Commercial Development at the Massachusetts Biotechnology
Research Institute (MBRI), Skip helped found seven life
sciences companies and created a unique technology licensing
office representing eight academic research institutions and
over $200 million in research. At Health Advances, Skip has
worked predominately with biopharmaceutical and drug
delivery clients. Skip graduated from the Massachusetts
College of Pharmacy and earned his MBA at the Amos Tuck
School at Dartmouth College. Skip was Director of Healthcare
Consulting at Arthur D. Little, Inc. where his professional
work involved technology planning, R&D management, and
strategic alliances. He previously worked in manufacturing
for Astra Pharmaceutical Products, Inc. He serves on
advisory boards of Mt. Auburn Hospital, and Andover Newton
Theological Seminary.
|
| Biotech Panel: Participant |
 |
Pierre Jacquet, M.D., Ph.D.
Vice President
L.E.K. Consulting Professionals |
Pierre Jacquet is a
Vice President in the Boston Office of L.E.K. Consulting.
He has over 5 years experience in corporate and business
unit strategy consulting, and mergers and acquisitions
advisory services. Prior to joining L.E.K., he was
with Arthur D. Little as a Manager of their pharmaceutical
practice.
Prior to consulting, Dr. Jacquet performed
business development for Genzyme. He was also a Fellow
in Cancer Surgery with the Washington Cancer Institute at
the Washington Hospital Center where he authored over 40
papers and book chapters about the pharmacology and
therapeutic use of chemotherapy for gastrointestinal
cancers.
Dr. Jacquet received his M.B.A. from Darden
Graduate School at the University of Virginia. He was
also awarded a Ph.D., Summa Cum Laude, in Biomedical
Sciences and a Doctor of Medicine, Magna Cum Laude, from the
University of Li¨¨ge in Belgium.
Dr. Jacquet is a Board
Member of Osprey Pharmaceuticals and is on the Advisory
Boards of T2C2/Sofinov Ventures and Seaflower Ventures.
|
| VC/Startup Panel: Participant |
 |
Samir Kaul
Partner, Flagship Ventures
Founding CEO, Codon Devices |
Samir joined Flagship Ventures while completing his MBA from Harvard Business School in 2001. From 1997-2000, he worked at the Institute for Genomic Research (TIGR) with Craig Venter. At TIGR, Samir led the Arabidopsis thaliana sequencing project, the first plant genome to be completely sequenced. He was also Chairperson of the Arabidopsis Genome Initiative and led the publication of the genome paper that appeared in Nature in 2000. In addition, Samir has been a lead and co-author on papers appearing in Nature, Science, and Proceedings of the National Academy of Sciences, and has been an invited and keynote speaker at a number of international conferences.
At Flagship, Samir focuses on early stage venture creation opportunities in the life science sector. He co-founded Helicos BioSciences, a single molecule sequencing company, with Noubar Afeyan, Eric Lander, Stan Lapidus and Steve Quake in 2003, and remains active in their business development activities. In early 2004, he was a co-founder and startup President of Epitome Biosystems, a protein analysis company, with Ruedi Aebersold and Richard DiMarchi. Currently, Samir is the founding CEO of Codon Devices, a new start-up backed by Flagship Ventures and Vinod Khosla. He also serves on the Board of Directors of Epitome and Codon Devices. In addition, Samir has played an active role in Flagship portfolio companies: BG Medicine, Genstruct, and Morphotek.
|
| Big Pharma Panel: Participant |
 |
Karim Lalji
VP Commercial Planning & Business Analysis
Sepracor, Inc. |
Karim F. Lalji is
currently Vice President, Commercial Planning and Business
Analysis at Sepracor, Inc. in Marlborough, Massachusetts. In
this capacity Karim is responsible for the management and
commercialization of the pipeline of drug candidates under
development by this specialty pharmaceutical company. Karim
is responsible for identifying which products to take into
development and managing them to ensure successful product
launches. Karim was the commercial architect for the
development of LUNESTA to treat insomnia. LUNESTA, launched
in 2005, is the most successful CNS drug launch in the
pharmaceutical industry. Additional products are under
development for depression, neuropathic pain, fibromyalgia,
anxiety, insomnia, hypertension, overactive bladder, asthma
and allergy. The Commercial Analytics function for which
Karim is responsible identifies key strategic analysis to
inform business decisions on sales force sizing and
marketing adjustments.
Prior to Sepracor, Karim was with Merck & Company for ten
years. At Merck, Karim led the worldwide launch team for
Crixivan ¨C a protease inhibitor for treatment of HIV/AIDS.
The Merck studies with Crixivan led to the discovery of the
¡°triple-cocktail¡± approach for treatment of HIV/AIDS. Karim
also subsequently had responsibility for the osteoporosis
franchise where he oversaw the worldwide marketing for
Fosamax and launch of new line extensions including Fosamax
Once Weekly.
Karim holds a Bachelors in Business Administration from
Simon Fraser University in Vancouver, British Columbia and a
Science Masters in Health Policy and Management from Harvard
University in Cambridge, Massachusetts. He was awarded the
Wilinsky Prize for Academic Excellence while at Harvard.
|
| Biotech Panel: Moderator |
 |
Jacques Mulder
Principal, New York
Life Sciences, Strategy & Operations
Deloitte Consulting, LLP |
Jacques has over 15
years of Life Sciences experience and he is guiding some of
Deloitte Consulting¡¯s most important engagements for leading
global pharmaceutical companies. He has deep experience
across the entire pharmaceutical value chain, particularly
in drug commercialization (U.S. and global) and post-launch
clinical research. Prior to joining Deloitte, Jacques served
as Senior VP of Integrated Strategic Solutions for a large
pharmaceutical research consulting firm. He has held
responsibility for several consulting functions, including
corporate strategy, R&D portfolio and marketing strategy,
clinical development, data management, bio statistics, and
site monitoring.
|
| Affiliated Service Providers Panel: Participant |
 |
Spencer Nam
Senior Research Analyst
Summer Street Research Partners |
Spencer Nam is a
senior research analyst at Summer Street Research Partners
covering medical supplies and devices companies. Spencer¡¯s
current focus areas include interventional cardiology,
orthopedics, wound care, and diagnostics. Prior to Summer
Street Research Partners, Spencer was a senior associate at
SG Cowen covering small and mid-cap medical supplies and
devices companies focusing on diagnostics sector. Prior to
SG Cowen, Spencer was an associate at Technology Directors,
Inc., an early stage venture capital firm, where he was
involved in evaluating opportunities in medical devices,
life science tools, telecommunications and energy. Prior to
joining TDI, Spencer was a consultant at Bain & Company in
Boston, advising senior managements of the Fortune 500
companies in areas of growth, mergers and acquisitions, and
new product development. Spencer received an AB in
mathematics from Harvard University and an MBA from Harvard
Business School.
|
| Affiliated Service Providers Panel: Moderator |
 |
Joseph P. Newhouse
Professor of Health Policy and Management
Harvard University John F. Kennedy School of Government |
Joseph P. Newhouse,
John D. MacArthur Professor of Health Policy and Management,
is head of the Interfaculty Initiative on Health Policy and
chairs the Committee on Higher Degrees in Health Policy,
which administers the PhD program in Health Policy at
Harvard. He edits the Journal of Health Economics, is a
member of the editorial board of The New England Journal of
Medicine, and has been a member and vice-chair of the
Medicare Payment Advisory Commission. He is a member of the
Institute of Medicine and is a Fellow of the American
Academy of Arts and Sciences. Newhouse was the first
recipient of the David Kershaw Prize of the Association of
Public Policy and Management and has received the
Distinguished Investigator Award of the Association for
Health Services Research, the Kenneth J. Arrow award, the
Zvi Griliches award, and the Paul A. Samuelson Certificate
of Excellence for various writings.
|
| Medical Devices Panel: Participant |
 |
James E. Nicholson
Founder, OrthoPlex, Mitek Surgical Products, Innovasive Devices, and Cortek |
James E. Nicholson,
BS, MS, MIT, is the Founder and Managing Partner of
OrthoPlex, LLC. Jim has an impressive track record in the
medical device industry as the founder of several medical
device start-up companies including Mitek Surgical Products,
Innovasive Devices, and Cortek, Inc. He is the inventor of
thirty eight patents, involving numerous enabling medical
and surgical products, including the Mitek Anchor and
Venodyne Intermittent Compression.
Jim led both Mitek and Innovasive through successful IPOs.
In 1994, Mitek was acquired by J&J's Ethicon division for
$128 million. In February, 2000 J&J¡¯s Ethicon Division
acquired Innovasive Devices for $85 million.
Jim's ability to develop innovative solutions for large,
unmet market needs is one key element of his success. He is
then able to attract Private and Venture Capital and hire a
team of experienced entrepreneurs to build the latest
venture. It is estimated that surgeons using Jim¡¯s products
have saved more than 250,000 lives. OrthoPlex is Jim's
seventh venture.
|
| Big Pharma Panel: Participant |
 |
Dr. Divakar Ramakrishnan
Director of Strategic Facilities Planning
Eli Lilly & Company |
Divakar Ramakrishnan
presently serves as Director of Strategic Facilities
Planning at Eli Lilly and Company, where he has
responsibilities spanning manufacturing strategy and
strategic planning activities supporting Lilly's Worldwide
Manufacturing Operations. He began his career at Lilly in
1998 as a Sr. Scientist in Lilly Research Laboratories and
was involved in the process scale-up and commercialization
activities supporting Lilly's biopharmaceutical portfolio.
He has had various assignments at Lilly including Research
Scientist, Head of Process Development (Molecular
Biology/Fermentation/Cell Culture). Divakar has a PhD in
Chemical Engineering from Pennsylvania State University and
a MBA from the Harvard Business School.
|
| Medical Devices Panel: Moderator |
 |
Frederick J. Schoen, M.D., Ph.D.
Professor of Pathology and Health Sciences and Technology
Harvard Medical School
Director of Cardiac Pathology and Executive Vice-Chairman in the Department of Pathology
Brigham and Women's Hospital |
Dr. Schoen is
Professor of Pathology and Health Sciences and Technology,
Harvard Medical School (HMS); Director of Cardiac Pathology
and Executive Vice-Chairman in the Department of Pathology
at the Brigham and Women's Hospital (BWH) in Boston; and a
member of the BWH-HMS faculty since 1980. His research
contributions have been in the areas of host-biomaterial
interactions, structure-function-pathology correlations in
heart valve substitutes and other cardiovascular prostheses,
calcification of bioprosthetic tissues, cardiovascular
tissue engineering, heart transplantation, and the pathology
of transgenic animal models of human cardiovascular disease.
Dr. Schoen has authored or co-authored over 400 scientific
manuscripts in journals and books, authored the book
Interventional and Surgical Cardiovascular Pathology:
Clinical Correlations and Basic Principles (1989); and
co-edited Biomaterials Science: An Introduction to Materials
in Medicine (1996, and 2nd Edition 2004), and Silver¡¯s
Cardiovascular Pathology, 3rd Edition (2001). He is
Past-President of the Society For Biomaterials (SFB) and the
Society for Cardiovascular Pathology (SCVP), was Founding
Fellow of the American Institute of Medical and Biological
Engineering, and has received the SFB Clemson Award for
Applied Biomaterials Research (1990), the SFB Founders
(Lifetime Research Achievement in Biomaterials) Award
(1999), and the Society for Cardiovascular Pathology
Distinguished Achievement Award (2006). He serves on many
national and international advisory committees, grant review
committees and editorial boards, and is consultant and
scientific advisor to numerous medical device companies. Dr.
Schoen has academic leadership responsibilities at BWH, HMS
and the Harvard-MIT Division of Health Sciences and
Technology (HST), and is an active teacher/director of
courses in pathology, cardiovascular pathology, and
biomaterials, medical devices and tissue engineering at
Harvard and MIT.
|
| Medical Devices Panel: Participant |
 |
Dr. John W. Sheets
Vice President and Chief Technical Officer
Ethicon, a Johnson & Johnson
company |
As the WWVP and Chief
Technical Officer for ETHICON, one of the largest Johnson &
Johnson medical device franchises, Dr. John Sheets is
responsible for the oversight of all technology for the
company's multi-billion dollar surgical products,
cardiovascular, women's health and wound management business
units. Prior to his career with Johnson & Johnson, Dr.
Sheets spent nearly a decade as Vice President, Surgical /IOL
& Therapeutics R&D with Alcon Laboratories, the world's
largest specialty ophthalmic company. Dr. Sheets received
his Ph.D. in Materials Science and Engineering from the
University of Florida and completed the Harvard Business
School's Program for Management Development.
|
| Biotech Panel: Participant |
 |
Phil Tinmouth
Senior Director of Corporate and Business Development
Vertex Pharmaceuticals |
Phil works at Vertex
Pharmaceuticals as Senior Director of Corporate & Business
Development. In this role, Phil is intricately involved with
the senior management team in assessing various corporate
development opportunities and developing both strategy and
long range plans. In addition to his Corporate Development
role, Phil has broad Business Development responsibilities
which include both Vertex's antibacterial and inflammation
portfolios, not only managing the sourcing and transactions
process but also managing business issues with international
collaborators.
Prior to joining Vertex, Phil worked at Bain & Company
(Boston) as a Manager in its Healthcare practice, serving
both Fortune 50 pharmaceutical clients as well as smaller
early development-stage biotech companies. These engagements
ranged in nature from post-merger integration to growth
strategy and M&A work.
Phil received an MBA from Harvard Business School and a
Bachelor of Science degree with Honours in Mechanical
Engineering with a minor in Chemical Engineering from
Queen's University in Kingston, Ontario. Phil lives in
Boston with his wife, Brit Dewey, and their son, Julian.
|
| Medical Devices Panel: Participant |
 |
Thomas J. Vasicek, Ph.D.
Senior Director, Biosciences Technology Development
Medtronic |
Thomas J. Vasicek,
Ph.D. is Senior Director of Biosciences Technology
Development at Medtronic, with the goal of discovering and
implementing new biotechnology opportunities for the
company. Dr. Vasicek comes to Medtronic with 25 years
experience in the biotechnology field. He has an extensive
peer-reviewed scientific publication list, and has
maintained premier collaborative research efforts with both
academia and industry throughout his career. Before joining
Medtronic, Dr. Vasicek was VP of business development at
Lynx Therapeutics, Inc. (now Solexa, Inc.), developing and
applying next generation DNA sequencing technologies for
high speed, economical, whole genome analysis. Prior to
Lynx, Dr. Vasicek served in various technology and business
development roles at Millennium Pharmaceuticals, Corning
Advanced Life Science Products, and LabSeek Scientific
Collaborative. Through the course of his career, Dr. Vasicek
has brokered numerous deals with big pharma, biotechs and
academia. He has also served as a business and technology
consultant for academic and commercial organizations around
the world. Dr. Vasicek received a B.S. degree in chemistry
from MIT and a Ph.D. in Genetics from Harvard University,
and completed postdoctoral training in developmental biology
at Princeton University.
|
| Affiliated Service Providers Panel: Participant |
 |
Cory Williams
Engagement Manager
McKinsey and Company |
Cory Williams is an
engagement manager in McKinsey and Company¡¯s New Jersey
office who has worked primarily on studies in the
pharmaceutical industry, including strategy, Medicare,
managed care, regulatory strategy, product launch, sales and
marketing and reimbursement strategy. Cory¡¯s non-healthcare
experience includes creating a go-to-market sales strategy
for a $13 billion Fortune 500 services company, product
liability strategy and setting priorities in education for a
government-related non-profit organization.
Prior to starting at McKinsey, Cory worked as a general
physician in a tertiary care medical center (Princess
Margaret Hospital, Government of the Bahamas). Cory holds a
D.Phil. in clinical medicine (oncology research) from the
University of Oxford, where he was a Rhodes scholar. He
received his medical degree from the University of the West
Indies (Mona, Jamaica), where he was a recipient of a
Bustamante Foundation scholarship.
|
| Affiliated Service Providers Panel: Participant |
 |
Tory Wolff
Senior Manager
Boston Consulting Group |
Tory Wolff is a
senior manager in BCG's health care practice. Based in
Boston, he has studied extensively the implications of MMA
of 2003 on the health care value chain including the the
biopharmaceutical sector and channels. He is a co-author of
studies on the impact of price controls in non-US OECD
countries. His clients include biopharmaceutical
manufacturers, PBMs, health care information companies, and
assorted Blue Cross and Blue Shield plans. Tory Wolff came
to BCG in 1998 after earning an MBA from The MIT Sloan
School of Management. Prior to business school, he founded
and operated an independent management consulting firm CEBA
Group in the Czech Republic. Tory also did graduate studies
in economics and politics at the University Mannheim and
earned a BA, cum laude, in history from Yale University.
Tory enjoys cross-country skiing, tennis and opera.
|
| Big
Pharma Panel: Moderator |
 |
Marta Wosinska
Assistant Professor
Harvard Business School |
Marta Wosinska
(pronounced: voh-SHEEN-skah) is an Assistant Professor at
the Harvard Business School where she teaches the required
first year MBA course in marketing. Her interest in
healthcare, particularly in pharmaceuticals, focuses on the
effectiveness of marketing instruments on patient
acquisition and retention. Her work on direct-to-consumer
advertising and on mail pharmacies has been received with a
considerable interest by pharmaceutical manufacturers,
health insurance companies and governmental agencies such as
the Food and Drug Administration and the Federal Trade
Commission. Her publications have appeared in leading
marketing and policy journals such as the Journal of
Marketing Research and Health Affairs.
Marta received her Ph.D. in Economics from University of
California at Berkeley. She also holds an undergraduate
business degree (B.S.) from Arizona State University. Prior
to starting her graduate studies, she worked as a sales and
customer service representative for a firm offering foreign
language training to large corporate clients.
|
|
|
|
|
